Lifescient is developing ivermectin, an anti-parasitic medication approved as a heartworm preventative in dogs and cats to treat COVID-19. Ivermectin is also approved in humans for the treatment of some parasitic infections and external parasites such as head lice. As the world grapples with vaccine distribution, Lifescient is working on a therapeutic alternative to combat COVID- 19. Another challenge is that viruses will continue to mutate creating new strains. These new variants may require the need for new vaccines and booster shots to be administered every year. Hence, a therapeutic option will play a critical role in containing the various strains of the virus year after year. The treatment that Lifescient is developing can be rapidly distributed globally without a cold supply chain which makes it less expensive and readily deployable worldwide.